Cell-Based Assays Market - Global Industry Analysis, Size, Growth and Forecast to 2023

Cell-based assays are commonly used analytical tools to measure the cell proliferation, viability, cytotoxicity, production and screening of compounds. Owing to the rise in cases of chronic disorders and increasing inclination of the government organizations and private firms funding in the health sector, there has been a consistent high demand of new therapeutic drug discovery. In this regard, the cell-based assays have advantage over the conventional animal based models for drug discovery. Cell-based assays utilizes live cell models to investigate the cellular mechanism when exposed to external stimuli and provide precise information about the intracellular molecular targets required in drug discovery screening.  In contrary to the animal based methods, the resultant toxicity and safety measures in cell based assays are monitored at an early stage of an experiment, hence it reduces the additional cost that can be generated due to high failure rates if monitored at a later stage of an experiment. In combination to high-throughput screening techniques, cell- based assays have gained its interest in the area of research and development for primary as well as secondary screening. However, cell-based assay’s experimental instruments and kits are expensive and require high skilled professionals to conduct the procedures as the cost of experimental procedure is relatively high. This acts as one of the key restraining factors governing the cell-based assays markets.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/cell-based-assays-market/report-sample

The global cell-based assays market is anticipated to grow on account of rise in the incidence of chronic diseases, increasing public and private intervention in the area of research and development, inclination towards cell-based assays over traditional biochemical assays, and a sustained increase in the drug discovery activity. According to the Centers for Disease Control and Prevention, 7 out of ten causes of death were due to chronic ailments, in 2014. Additionally, the cell-based assay techniques have many advantages over conventional methodology. The continuous advancement in technological products under cell-based assay along with their cost effectiveness are the major drivers of the growth of global cell-based assays market.

Certain factors such as, the involvement of developing countries in the Asia-Pacific region such as China and India, advancement in technology such as emergence of 3D cell-based assays, increase in demand of toxicological testing of screened compounds in drug discovery along with the varied application of cell-based assays present a vast opportunity for the manufacturers in the global cell-based assays market.

Explore Report at: https://www.psmarketresearch.com/market-analysis/cell-based-assays-market

Some of the other major players operating in the global cell-based assays market include Merck KGaA, Becton, Dickinson and Company, Promega Corporation, Danaher Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Cell Signaling Technology, Inc., BioTek Instruments Inc., Lonza Group, ProQinase GmbH, Charles River Laboratories Inc, Cisbio Bioassays, Miltenyi Biotec, Cell Biolabs, Inc.,  DiscoverX Corporation, BioAgilytix Labs., Enzo Life Sciences, Inc., Aurelia Bioscience Ltd., Selexis SA, and QGel SA.

Blood Group Typing Market Segmentation, Key Players, Analysis and Forecast to 2023

Blood plasma product is the extracted portion from the blood using fractionation process to deliver products rich in plasma proteins. These products are used as body fluids, antibodies and clotting factors in medical industries that aid in treatment of chronic ailments like auto-immune disorders and haemophilia. The global blood plasma product market is expected to witness a significant growth during the forecast period due to the high demand by a large pool of patients with no alternative therapeutic approach. Blood plasma product have a wide range of components that have clinical use such as, Albumin, Factor VIII, Factor IX, immunoglobulin, fibrinogen with their major applications in bleeding disorders (haemophilia, immunological disorders), massive hemorrhage and in traumatic injuries. Moreover, the presence of biomarkers in plasma adds to their application in clinical diagnosis of diseases. These factors will drive the growth of global blood plasma product market in future.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/blood-plasma-product-market/report-sample

According to a report by World Federation of Haemophilia, there are 304,362 people suffering from bleeding disorders such as, haemophilia, von Willebrand disease and others. The statistics depict 5.6% increase in prevalence of diseases from 2014-2015. The present therapeutics involve a continuous supply of plasma product as supplement. This increase in prevalence of bleeding disorders will drive a positive impact on the growth of the market during the forecast period 2017-2023. Moreover, government and private organization support blood donation programs to meet the rising demand of plasma, which will further drive the market growth. The growth of geriatric population results in the increase in prevalence of age related diseases such as, kidney disorder that requires blood plasma product as a therapeutic. These factors will drive the growth of the global blood plasma product market.

The identification of new proteins in blood plasma to be used as therapeutic products are under clinical investigation. This will provide opportunity to companies to maximize the volume of blood plasma fractionation. Further, exploring novel therapeutic application of the known blood plasma product to be used for other diseases will also provide ample opportunities to the market players to invest and expand in the global market.

Explore Report at: https://www.psmarketresearch.com/market-analysis/blood-plasma-product-market

In June 2017, CSL Ltd., announced its first acquisition in Chinese market by acquiring Wuhan Zhong Yuan Rui De Biological Products Co. Ltd., a subsidiary of Humanwell Healthcare Co. Ltd. This will expand CSL Ltd. plasma collection and product portfolio in Asia Pacific’s blood plasma product market.

The other key players in the global market are Shire Pls., Octapharma AG, Kedrion S.p.A, Biotest AG, China Biologic Products, Inc., Sanquin and LFB S.A.

Surgical Navigation System Market - Global Industry Analysis, Drivers, Trends and Forecast to 2023

Global surgical navigation system market is forecasted to attain revenues of $1046.8 million value by 2023. The growth in the market will be led by the rising prevalence of orthopedic, neurological, and ENT disorders, increasing adoption of minimally invasive surgical procedures, rising aging population, technological advancements, and increasing regulatory approval for navigation systems, that can be used in various surgeries.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/surgical-navigation-system-market/report-sample

The surgical navigation system market has been categorized into optical, electromagnetic and hybrid navigation systems, based on technology, where optical navigation systems are expected to witness the fastest growth in demand, at CAGR of 7.3% during the forecast period. The demand for optical navigation systems is expected to grow continuously, since the surgeons can perform interventions with greater safety and precision, and this method also minimizes radiation exposure to the patient as well as the staff in operation room.

Asia-Pacific surgical navigation system market is expected to witness fastest growth, mainly due to aging population, rising incidence of burns cases, increasing diabetic patients, and per capita income. Elderly people have a slow healing of wounds as they have reduced regenerative capabilities and weak immune system, which leads to different ailments, thereby boosting the market for surgical navigation systems in the region. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the number of people aged 65 years and above, constituted approximately 11.4% of population in 2013, and the count is estimated to reach approximately 20% of the population by 2050.

Explore Report at: https://www.psmarketresearch.com/market-analysis/surgical-navigation-system-market

Some of the other key players operating in the surgical navigation system market include Koninklijke Philips N.V., Fiagon GmbH, Orthalign, Inc., Stryker Corporation, Scopis GmbH, Medtronic plc, Siemens AG, General Electric Company, B. Braun Melsungen AG and Zimmer Biomet Holdings, Inc.

Stem Cell Banking Market Drivers, Restraints, Opportunities and Challenges

Stem cells are the cells that have the potential to differentiate into various types of cells in the body. Embryonic stem cells and adult stem cells are the two main types of stem cells. Stem cells could possibly be used to generate cells and tissues for therapy of a variety of diseases including Alzheimer's disease, Parkinson's disease, heart disease, spinal cord injury, diabetes, and arthritis. The global stem cell banking market is expected to grow due to the increasing prevalence of such diseases and increasing awareness among people about the need to preserve stem cells. The umbilical cord blood of the newborn is an abundant source of stem cells. However, some tissues and organs within body, skin, blood, and the lining of intestine are also key source of tissue-specific stem cells. The stem cells are separated from the blood or tissue, processed, tested and preserved in a stem cell bank.

Get Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/stem-cell-banking-market/report-sample

The stem cell market is expected to grow during the forecast period mainly due to the easy extraction methods used and increasing awareness about stem cell therapeutics and their potential in treating various diseases. According to World Health Organization (WHO), cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases in 2012 and the number of new cases are expected to rise by about 70% over the next two decades. With promising results with stem cell therapies in treating such disorders, the increased incidence of these disease is expected to act as a driving factor for the growth of the global stem cell banking market.

The rising awareness about potential use of cord tissue, collaborations of cord blood banks to gain a larger market share and the with the introduction of various automated procedures being developed in the field of science are expected to provide abundant opportunities to the manufacturers in the global stem cell banking market. In June 2017, Americord started a social media campaign for National Cord Blood Awareness Month to create awareness about various diseases currently being treated with cord blood stem cells.

Explore Report at: https://www.psmarketresearch.com/market-analysis/stem-cell-banking-market

Some of the major players operating in the stem cell banking market include Cordlife Group Ltd, Cryocell International, Inc., Lifecell International Pvt. Ltd., PerkinElmer, Inc. (Viacord), StemCyte Inc., CryoSave AG, China Cord Blood Corporation, Cord Blood America, Inc., Caladrius Biosciences Inc., CBR Systems, Inc., Cordvida, Cordviva India.

Asia-Pacific Scar Treatment Market Analysis, Share, Growth and Forecast to 2023

The Asia-Pacific scar treatment market size was valued at $3.6 billion in 2016, which is forecasted to reach $7.8 billion by 2023, growing at a CAGR of 11.6% during the 2017-2023. Among the various types of scar treatments, topical scar treatment is expected to lead the scar treatment market in the region, followed by surface, laser, injectable, and invasive surgical treatment.  Increasing focus on personal well-being, rising awareness about scar treatments and growing availability of non-invasive and less expensive topical scar treatment products are expected to be the drive the demand for topical scar treatment products.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/asia-pacific-scar-treatment-market/report-sample

The Asia-Pacific scar treatment market is expected to grow at a faster rate as compared to other regions, due to increasing focus of general population on personal well-being, rising disposable income and growing prevalence of skin related problems such as burns, wounds and increasing number of cosmetic procedures performed in the region. According to the WHO, approximately 1,000,000 people suffer from moderate or severe burns, every year. These burn cases may lead to scar formation, leading to increased demand for scar treatment products in the region. According to the International Society of Aesthetic Plastic Surgery (ISAPS), the cosmetic surgeries performed in countries such as South Korea and India, are increasing at a rapid rate. In 2015, total surgical procedures performed in South Korea was 445,144, and in India, the number stood at 420,454.

A. Menarini Asia-Pacific Holdings Pte. Ltd. offers Dermatix Ultra, a scar formula that uses the innovative CPX (cyclopentasiloxane) technology for improved effects in flattening and softening scars and holds Vitamin C providing photoprotection and skin lightening. With companies using innovative technologies for scar treatments, the demand for advanced scar treatment products is likely to increase during the forecast period.

Explore Report at: https://www.psmarketresearch.com/market-analysis/asia-pacific-scar-treatment-market

The key players operating in the Asia-Pacific scar treatment market include Shanghai Fosun Pharmaceutical (Group) Company Limited, Beijing Toplaser Technology Company Limited, Sirnaomics, Inc., Essex Bio-Technology Limited, A. Menarini Asia-Pacific Holdings Pte. Ltd, Shiseido Company Limited, Concord Medisys Pvt. Ltd, Seoulin Bioscience Co. Ltd., Hanson Medical Inc., Otsuka Pharmaceutical Co., Ltd.

Single-Use Bioprocessing Systems Market Key Players, Segments Analysis, Growth Drivers and Forecast to 2023

Rising demand of disposables in biopharmaceutical production, increasing prevalence of chronic diseases, which requires biological drugs for their management and treatment, low manufacturing costs of disposable products and instrument, and improving life science research infrastructure are some of the growth drivers of the global single-use bioprocessing systems market. In addition, technological advancement in bioprocessing systems is also driving the growth of global single-use bio-processing systems market. Increasing numbers of mergers and acquisitions and rapid product launches are some of the major trends, observed in the global single-use bioprocessing systems market.

Get Sample Copy of this Research Report@ https://www.psmarketresearch.com/market-analysis/single-use-bioprocessing-systems-market/report-sample

Europe and North America are the major markets for single-use bioprocessing systems, attributed to the increased life science research and growing demand for biopharmaceuticals. Asia-Pacific market for the single-use bioprocessing systems is growing at a significant rate owing to improving life science infrastructure and increasing investment by several pharmaceutical manufacturing companies for the development of R&D plants in the region. Apart from these regions, Latin America and Middle-East are other important markets of single-use bio-processing systems.

Explore Report at: https://www.psmarketresearch.com/market-analysis/single-use-bioprocessing-systems-market

Some of the major players operating in global single-use bioprocessing systems market include Tarpon Biosystems Inc., GE Healthcare, STI Components Inc., Merck & Co Inc., Saint-Gobain Corporation, Sartorius Stedim Biotech SA, PendoTECH, ThermoFisher Scientific Inc., Parker Hannifin Corporation, Pall Corporation, Eppendorf AG, Cellexus Ltd. and Broadley-James Ltd.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook

Biophotonics Market Growth Factors, Consumption, Market Current Scenario and Forecast to 2023

Global biophotonics market is growing significantly due to advancement in optical technology, high incidences of chronic diseases, and increasing demand for minimally invasive surgeries. The massive unexplored biophotonics market in the emerging economies and large number of non-medical applications of biophotonics are creating ample opportunities for the growth of the global biophotonics market. The advanced research and development facilities and new product development by the key market players are propelling the demand for cost effective biophotonics instruments, thus fuelling the growth of the global biophotonics market.

Get Report Sample at: https://www.psmarketresearch.com/market-analysis/biophotonics-market/report-sample

Biophotonics refers to the development of optical techniques for studying, imaging and detecting, various biomolecules, cells and tissues. Biophotonics is the combination of photonics and biology. It utilizes photons (light) to study the inner working of biological materials, such as cells and tissues. Biophotonics has a range of applications ranging from medicine to food, and molecular biology to agriculture. The applications of biophotonics in medicine include detection, diagnosis and treatment of various diseases. In the food and agriculture industry, biophotonics is primarily used to detect pathogens; whereas in molecular biology, biophotonics is used to study and understand the functions and mechanisms of DNA, protein and other biomolecules.

Asia-pacific is the fastest growing region in the global biophotonics market. The major reasons for the fastest growth of the Asia-Pacific biophotonics market are increasing research and development activities, growing usage of biophotonics techniques in food industry, and up surging healthcare expenditure. Moreover, the biophotonics market in the region is growing rapidly, due to high prevalence of chronic diseases, increasing geriatric population and improving healthcare infrastructure in the emerging economies, such as India and China.

Explore Report at: https://www.psmarketresearch.com/market-analysis/biophotonics-market

The major players operating in the global biophotonics market are Hamamatsu Photonics K.K., Becton Dickinson and Company, PerkinElmer Inc., Oxford Instruments PLC, OLYMPUS CORPORATION, Affymetrix Inc., and Carl Zeiss Stiftung.

Wnt Signaling Pathway Inhibitors Therapeutics Pipeline Review 2017

The study analyzed that the Wnt signaling pathway inhibitors therapeutics pipeline comprises approximately 26 drug candidates in different stages of development. Wnt or β-Catenin signaling pathway plays an important role in the development of pluripotent cells. The signaling pathway was earlier named as Wingless (Wng) in Drosophila and Int1 in the mouse. Wnt proteins consist of several glycoproteins that have conserved cysteine residues. There are 19 human Wnt genes that encode spliced isoforms. Wnt proteins bind to the Frizzled (Fz) receptors which forms the complex with low-density lipoprotein receptor-related protein (LRP).

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/wnt-signaling-pathway-inhibitors-therapeutics-pipeline-analysis/report-sample

The positive clinical results of Wnt signaling pathway inhibitors drug candidates are driving the pipeline growth. Samumed, LLC announced the successful completion of a 52-week Phase II clinical trial of its potential treatment for osteoarthritis of the knee. SM04690 is a novel, small molecule inhibitor of the Wnt signaling pathway, administered as an intra-articular injection. SM04690 appeared to be safe and well-tolerated at all dose levels studied.

In July 2017, Oncology Venture AB and 2X Oncology, Inc. entered into an exclusive global license agreement with Eisai Inc. for Eisai's Phase II PARP inhibitor E7449 - now called 2X-121. 2X-121 would be developed by 2X Oncology, Inc., a precision medicine company developing targeted therapeutics to address significant unmet needs in women's cancer.

Explore Report at: https://www.psmarketresearch.com/market-analysis/wnt-signaling-pathway-inhibitors-therapeutics-pipeline-analysis

Some of the key players developing drugs for the treatment of Wnt signaling pathway inhibitors therapeutics include Samumed, LLC, Can-Fite BioPharma Ltd., Tactical Therapeutics, Inc. and others.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Androgenic Alopecia Therapeutics Pipeline Review 2017 - P&S Market Research

The study analyzed that the androgenic alopecia therapeutics pipeline comprises approximately 24 active drug candidates in different stages of development. Androgenic alopecia is a genetic disorder that affects both men and women and is characterized by hair loss in both the sexes. Androgenic alopecia is also known as male-pattern baldness in men and female-pattern baldness in women. The predisposing factors for androgenic alopecia include allergies, burns, irritants, injuries, infections, and toxins.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/androgenic-alopecia-therapeutics-pipeline-analysis/report-sample

The positive clinical results of androgenic alopecia drug candidates have been driving the pipeline growth. Many drug candidates have shown positive clinical results and are proceeding further towards development. In February 2016, Cassiopea S.p.A. reported the top-line results from the proof of concept, Phase II clinical trial of Breezula (CB-03-01), in androgenic alopecia and it was found that Breezula, met both its two pre-defined co-primary efficacy endpoints, increase in total area hair count within 1 cm2 (TAHC) and subject hair growth assessment (HGA) at six months. Breezula also demonstrated favorable safety profile.

In August 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., a privately held biotechnology company for a consideration of $10 million in cash and issued approximately 350,000 shares of its common stock, with a value of approximately $10 million on the closing date to expand the dermatological pipeline of Aclaris Therapeutics, Inc.

Explore Report at: https://www.psmarketresearch.com/market-analysis/androgenic-alopecia-therapeutics-pipeline-analysis

Some of the key players developing drugs for the treatment of androgenic alopecia therapeutics include GlaxoSmithKline plc, Almirall S.A., Allergan plc, RepliCel Life Sciences Inc. and others.

Liver Cirrhosis Therapeutics - Pipeline Analysis 2018

Liver cirrhosis is a condition in which liver deteriorates and gradually ceases the liver function. The healthy tissues of the liver are replaced by the scar tissues that block the blood flow in the liver. The main functions of the liver include removal of waste products, making new proteins, producing bile, and processing of the nutrients. The building up of scar tissue gets worse throughout the period and causes chronic liver failure which is also known as end stage liver disease. Chronic hepatitis C, alcoholism, non-alcoholic fatty liver disease, chronic hepatitis B and autoimmune liver disease are observed as the major causes of liver cirrhosis. Liver cirrhosis can be symptomatized by weakness, fatigue, weight loss, bloating of the abdomen, jaundice, itching, and nausea. Rohto Pharmaceutical Co., Ltd. is in the process of developing mesenchymal stem cell as a cell therapy for the treatment of liver cirrhosis. Pfizer, Inc. is in the process of developing pregabalin as a CACNA2D1 protein modulators for the treatment of liver cirrhosis. Some of the companies having the pipeline of liver cirrhosis include Conatus Pharmaceuticals, Inc., Pfizer, Inc., Prism Pharma Co., Ltd., and others.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/liver-cirrhosis-therapeutics-pipeline-analysis/report-sample

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Ambulatory EHR Market - New Business Opportunities & Investment Research Report 2023

The global ambulatory EHR market is forecasted to attain a value of $6.0 billion by 2023, growing at a CAGR of 5.9% during 2017-2023. The growth in the market will be led by increasing government initiatives for the adoption of EHR systems, rising adoption of healthcare intranet technologies (HCIT), rising usage of EHR solutions, and need to reduce the overall healthcare cost.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/ehr-market/report-sample

The two-different delivery modes for ambulatory EHR solutions are cloud based solutions and on-premise solutions, with the cloud based category being the larger contributor to the ambulatory EHR market. Cloud based solutions are also projected to register faster growth compared to on-premise solutions, during the forecast period. Among the various practice size, small-to-medium sized practices is expected to register the fastest growth during the forecast period, mainly due to increasing adoption of EHR solutions.

Asia–Pacific is expected to be the fastest growing region in the global ambulatory EHR market due to aggressive investments by the governments, non-profit entities and the private sector in EHR systems, growing aging population, and rising incidence of chronic diseases in various countries, such as India and China.

Globally, the key players in the ambulatory EHR market are launching new products to gain a larger market share. For instance, in June 2017, eClinicalWorks, a provider of healthcare IT solutions, launched a telehealth solution on the company’s Health & Online Wellness (HEALOW) mobile app to provide patients with live video visits.

Explore Report at: https://www.psmarketresearch.com/market-analysis/ehr-market

Some of the other key players operating in the ambulatory EHR industry include General Electric Company, Cerner Corporation, Epic Systems Corporation, Mckesson Corporation, Quality Systems, Inc., eMDs Inc., Allscripts Healthcare Solutions, Inc., Greenway Health, LLC.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Pompe Disease Therapeutics Pipeline 2018 - Clinical Trials, Designation, Collaboration and Developments

Pompe Disease is a genetic disorder that is caused by building up of glycogen in body’s organs and tissues. This further leads to impairment of the ability to function normally. According to the researchers, there are three types of pompe disease, including non-classic infantile-onset, late-onset, and classic infantile-onset. The non-classic infantile-onset pompe disease is generally characterized by delayed motor skills. The classic form of infantile-onset pompe disease causes myopathy, hypotonia, and hepatomegaly. The late-onset type of pompe disease is generally milder than infantile-onset forms and causes progressive muscle weakness. Valerion Therapeutics, LLC is in the process of developing VAL-1221 for the treatment of pompe disease. Sanofi SA is in the process of developing GZ402666 for the treatment of pompe disease. Some of the companies and universities having the pipeline of pompe disease include University of Florida, Sanofi SA, and others.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/pompe-disease-therapeutics-pipeline-analysis/report-sample

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Explore Report at: https://www.psmarketresearch.com/market-analysis/pompe-disease-therapeutics-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Portal Hypertension Therapeutics - Pipeline Analysis, Clinical Trials, Patent and Developments

Portal hypertension is a disorder in which pressure in portal vein and tributaries is increased and portal pressure gradient is more than 10 mmHg. The portal pressure gradient predicts the decompensation of cirrhosis, hepatocellular carcinoma, and development of varices. The development of gastroesophageal varices, one of the consequences of portal hypertension, can cause variceal haemorrhage. There are three types of portal hypertension, including intrahepatic, post-hepatic and pre-hepatic. Portal hypertension is one of the complications of the liver disease. Aga Khan University is in the process of developing carvedilol as a non-selective beta-adrenergic receptor blocker (β1, β2) and an alpha-adrenergic receptor blocker (α1), for the treatment of portal hypertension. Ferring Pharmaceuticals, Inc. is in the process of developing FE 204205 as a vasopressin 1a receptor agonist for the treatment of portal hypertension. Some companies and universities having the pipeline of portal hypertension include Ferring Pharmaceuticals, Inc., Cumberland Pharmaceuticals, Inc., and others.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/portal-hypertension-therapeutics-pipeline-analysis/report-sample

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Explore Report at: https://www.psmarketresearch.com/market-analysis/portal-hypertension-therapeutics-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook